ravagalimab (ABBV-323) - AbbVie
Ravagalimab: Initiation of P3 trial for ulcerative colitis in 2021 (AbbVie) - Feb 8, 2020 - Pipeline Update: Proof-of-concept data from P2 trial (NCT03695185) for ulcerative colitis in 2020 
New P3 trial • P2 data
https://investors.abbvie.com/static-files/0f2e0201-ef33-432c-904e-8cf78d2d0929
 
Feb 8, 2020
 
 
65cbd4d4-6c06-4411-8711-097690a645e6.jpg